Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
Wake, Durham, Orange, Franklin, and Granville counties are under alert.
Breaking News
Severe thunderstorm warning in effect for Durham, Orange & Granville counties until 6:15 p.m.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
120.89
+0.47 (+0.39%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
28
29
Next >
Current Report: Novartis (NVS)
May 17, 2022
Novartis’s price per share was $87.81 as of yesterday's market close. One year ago its price was $88.85.
Via
Talk Markets
5 Value Stocks In The Healthcare Sector
May 16, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
3 Undervalued Stocks to Buy Before You Sell in May and Go Away
May 13, 2022
If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy.
Via
InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
May 12, 2022
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
Via
Investor's Business Daily
5 Value Stocks To Watch In The Healthcare Sector
May 09, 2022
What Defines a Value Stock?
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
May 09, 2022
Upgrades
Via
Benzinga
New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting
May 04, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
April 27, 2022
Via
Benzinga
Novartis: Q1 Earnings Insights
April 26, 2022
Novartis (NYSE:NVS) reported its Q1 earnings results on Tuesday, April 26, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Here's The Surprising Source Of Novartis' First-Quarter Sales Growth
April 26, 2022
An unexpected business contributed 8% to Novartis' first-quarter sales growth.
Via
Investor's Business Daily
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
April 27, 2022
Via
Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For April 26, 2022
April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million.
Via
Benzinga
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
April 26, 2022
Via
Benzinga
Novartis Earnings Preview
April 25, 2022
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report...
Via
Benzinga
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
April 22, 2022
Via
Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
April 21, 2022
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Golden Cross Appears Before Novartis Investors
April 14, 2022
If history is any guide, there may be good fortune ahead for shares of Novartis (NYSE:NVS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
Hopeful Golden Cross Forms On Novartis's Chart
April 14, 2022
If history is any guide, there may be good fortune ahead for shares of Novartis (NYSE:NVS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
Biogen’s Aduhelm Crashes the Biotech Sector
April 13, 2022
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock.
Via
InvestorPlace
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
April 12, 2022
Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
April 11, 2022
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
April 08, 2022
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.
Via
InvestorPlace
Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication
April 06, 2022
The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS)...
Via
Benzinga
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.